Phibro Animal Health Corporation
PAHCAnalyst Consensus
Price Target Trend
Rating Trend
Recent Price Targets
| Date | Firm | Analyst | Target | Price Then | Source |
|---|---|---|---|---|---|
| Feb 6, 2026 | Morgan Stanley | $49.00(-9%) | $53.66 | TheFly | |
| Aug 28, 2025 | Morgan Stanley | $34.00(-12%) | $38.46 | TheFly | |
| Jun 25, 2025 | Morgan Stanley | $26.00(+5%) | $24.75 | TheFly | |
| Apr 15, 2025 | Morgan Stanley | Erin Wright | $20.00(+19%) | $16.81 | TheFly |
| Dec 21, 2022 | Roth Capital | $18.00(+41%) | $12.75 | Benzinga | |
| Sep 16, 2022 | Barclays | $17.00(+19%) | $14.29 | Benzinga | |
| Aug 26, 2022 | Morgan Stanley | $21.00(+31%) | $16.06 | Benzinga |
Recent Rating Actions
| Firm | Action | Rating | Date |
|---|---|---|---|
| Citigroup | maintain | Neutral | May 14, 2026 |
| JP Morgan | maintain | Overweight | Nov 7, 2025 |
| B of A Securities | maintain | Underperform | Aug 29, 2025 |
| JP Morgan | upgrade | Neutral →Overweight | Jul 7, 2025 |
| Morgan Stanley | maintain | Equal Weight | Jun 25, 2025 |
| Morgan Stanley | maintain | Equal Weight | May 8, 2025 |
| Barclays | maintain | Underweight | Feb 10, 2025 |
| Morgan Stanley | maintain | Equal Weight | Dec 17, 2024 |
| Barclays | maintain | Underweight | Nov 12, 2024 |
| B of A Securities | maintain | Underperform | Aug 30, 2024 |
| Barclays | maintain | Underweight | May 10, 2024 |
| Morgan Stanley | maintain | Equal Weight | Nov 9, 2023 |
| Roth MKM | maintain | Buy | Sep 1, 2023 |
| Morgan Stanley | maintain | Equal Weight | Aug 31, 2023 |
| Roth MKM | maintain | Buy | Aug 29, 2023 |
| Morgan Stanley | maintain | Equal Weight | Jul 27, 2023 |
| Morgan Stanley | maintain | Equal Weight | May 4, 2023 |
| Morgan Stanley | maintain | Equal Weight | Feb 9, 2023 |
| Roth Capital | maintain | Buy | Dec 21, 2022 |
| Morgan Stanley | maintain | Equal Weight | Nov 10, 2022 |
| Barclays | maintain | Underweight | Sep 16, 2022 |
| Morgan Stanley | maintain | Equal Weight | Aug 26, 2022 |
| Barclays | downgrade | Equal Weight →Underweight | Jul 25, 2022 |
| Barclays | upgrade | Underweight →Equal Weight | Jan 10, 2022 |
| Morgan Stanley | maintain | Equal Weight | Nov 18, 2021 |
Earnings History
Next report: Feb 3, 2027 · EPS est. $0.94| Report Date | EPS Actual | EPS Est. | Revenue Actual | Revenue Est. |
|---|---|---|---|---|
| Nov 4, 2026 | $0.79 | $0.78 | $386.8M | $382.4M |
| Aug 26, 2026 | $0.85 | $0.71 | $396.7M | $381.2M |
| May 6, 2026 | $0.76 | $0.72 | $383.5M | $367.0M |
| Feb 4, 2026 | $0.87 | $0.69 | $373.9M | $355.6M |
| Nov 5, 2025 | $0.73 | $0.59 | $363.9M | $347.0M |
| Aug 27, 2025 | $0.57 | $0.52 | $378.7M | $362.4M |
| May 7, 2025 | $0.63 | $0.52 | $347.8M | $352.2M |
| Feb 5, 2025 | $0.54 | $0.40 | $309.3M | $292.3M |
News
Phibro Animal Health Corporation ( PAHC ) Q1 2027 Earnings Call November 5, 2026 9:00 AM EST Company Participants Glenn David - Chief Financial Officer Patrick Rodriguez - Vice President of Finance & Treasurer Daniel Bendheim - CEO, President & Director Larry Miller - Chief Operating Officer Conference Call Participants Ekaterina Knyazkova - JPMorgan Chase & Co, Research Division Curtis Moiles - BNP Paribas, Research Division Presentation Operator Hello, everyone. Thank you for joining us, and w…
Although the revenue and EPS for Phibro (PAHC) give a sense of how its business performed in the quarter ended September 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
TEANECK, N.J.--(BUSINESS WIRE)--Phibro Animal Health Corporation (Nasdaq: PAHC) (“Phibro” or the “Company”) today announced financial results for its first quarter ended September 30, 2026 and maintained its financial guidance for the year ending June 30, 2027. Highlights for the three months ended September 30, 2026 (compared to the three months ended September 30, 2025) Net sales of $386.8 million, an increase of $22.9 million, or 6% Net income of $29.5 million, an increase of $3.0 million, o.
TEANECK, N.J.--(BUSINESS WIRE)--The Board of Directors of Phibro Animal Health Corporation (Nasdaq: PAHC) today declared a quarterly cash dividend of $0.12 per share on its Class A common stock and Class B common stock, payable on December 16, 2026, to stockholders of record at the close of business on November 25, 2026. About Phibro Animal Health Corporation Phibro Animal Health Corporation is a leading global diversified animal health and nutrition company. We strive to be a trusted partner w.
TEANECK, N.J.--(BUSINESS WIRE)--Phibro Animal Health Corporation (Nasdaq: PAHC) expects to announce its first quarter financial results on Wednesday, November 4, 2026, after the market closes. Phibro management will host a conference call and webcast on Thursday, November 5, 2026, at 9:00 AM Eastern Time. Interested parties are invited to listen to the conference call and view the presentation slides by visiting https://investors.pahc.com. The discussion will also be available by dialing +1 (83.
Phibro (PAHC) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Investors interested in stocks from the Medical - Products sector have probably already heard of Phibro Animal Health (PAHC) and Stryker (SYK). But which of these two stocks presents investors with the better value opportunity right now?
Investors with an interest in Medical - Products stocks have likely encountered both Phibro Animal Health (PAHC) and Haemonetics (HAE). But which of these two stocks presents investors with the better value opportunity right now?
Tvardi Therapeutics (NASDAQ: TVRD - Get Free Report) and Phibro Animal Health (NASDAQ: PAHC - Get Free Report) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, risk, profitability, institutional ownership, analyst recommendations, dividends and earnings. Insider and Institutional Ownership 44.7% of
SEI, SDRL and PAHC made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on September 21st, 2026.
Investors interested in stocks from the Medical - Products sector have probably already heard of Phibro Animal Health (PAHC) and Haemonetics (HAE). But which of these two stocks presents investors with the better value opportunity right now?
Engineers Gate Manager LP boosted its position in Phibro Animal Health Corporation (NASDAQ: PAHC) by 112.8% during the undefined quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 52,914 shares of the company's stock after purchasing an additional 28,052 shares during the quarter.
DiamondRock Hospitality, Vertiv, Mueller Water Products and Phibro Animal Health stand out for strong interest coverage as Treasury yields rise.
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
TEANECK, N.J.--(BUSINESS WIRE)--Phibro Animal Health Corporation (Nasdaq: PAHC) announced today it will participate in the Morgan Stanley Annual Global Healthcare Conference. President & Chief Executive Officer, Daniel Bendheim; Chief Operating Officer, Larry Miller; and Chief Financial Officer, Glenn David will address financial analysts and investors on Tuesday, September 15, 2026, at 1:05 PM ET at New York Marriott Marquis in New York. The live audio presentation will be available on the.
Investors interested in stocks from the Medical - Products sector have probably already heard of Phibro Animal Health (PAHC) and LeMaitre Vascular (LMAT). But which of these two stocks is more attractive to value investors?
Phibro Animal Health's Zoetis MFA acquisition has created a larger animal health platform with stronger earnings and broader manufacturing reach. Vaccines, nutritional specialties, and companion-animal expansion give PAHC newer growth verticals beyond the legacy MFA franchise. Management's optimization program and Chicago Heights consolidation could improve efficiency as the acquired portfolio moves beyond integration.
Phibro Animal Health (NASDAQ: PAHC) reported record fiscal 2026 sales and a sharp increase in adjusted EBITDA, supported by growth in its Animal Health and Mineral Nutrition businesses, the integration of its acquired Zoetis medicated feed additive portfolio, and operational initiatives under its Phibro Forward program. For the fiscal year ended June 30, 2026, Phibro posted
Phibro Animal Health Corporation (PAHC) Q4 2026 Earnings Call Transcript
Phibro Animal Health NASDAQ: PAHC reported record fiscal 2026 sales and a sharp increase in adjusted EBITDA, supported by growth in its Animal Health and Mineral Nutrition businesses, the integration of its acquired Zoetis medicated feed additive portfolio, and operational initiatives under its Phibro Forward program.